6 days Ago By Defense World Staff
Wellington Management Group LLP increased its holdings in shares of ADC Therapeutics SA ( NYSE:ADCT – Free Report ) by 50.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 253,342 shares of the company’s stock after buying an additional 84,785 shares during the period.
Wellington Management Group LLP owned about 0.26% of ADC Therapeutics worth $504,000 at the end of the most recent quarter. A number of other hedge funds also recently modified their holdings of ADCT.
Prudential Financial Inc. acquired a new position in shares of ADC Therapeutics in the 4th quarter worth approximately $35,000. LPL Financial LLC bought a new stake in shares of ADC Therapeutics during the fourth quarter valued at approximately $50,000.
Sei Investments Co. acquired a new position in ADC Therapeutics during the fourth quarter worth $46,000. Kazazian Asset Management LLC bought a new position in ADC Therapeutics in the 4th quarter valued at about $26,000.
Finally, Platinum Investment Management Ltd. boosted its position in shares of ADC Therapeutics by 11.6% during the fourth quarter.
Platinum Investment Management Ltd. now owns 1,612,556 shares of the company’s stock valued at $3,209,000 after buying an additional 168,040 shares during the last quarter. Institutional investors and hedge funds own 41.
10% of the company’s stock. Analysts Set New Price Targets Several equities analysts have commented on ADCT shares. Stephens lifted their target price on shares of ADC Therapeutics from $6.
00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Guggenheim lowered their price target on shares of ADC Therapeutics from $10.
00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, March 31st. HC Wainwright restated a “buy” rating and issued a $8.
00 target price on shares of ADC Therapeutics in a research note on Monday, March 31st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ADC Therapeutics in a research report on Friday, March 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat.
com, the company presently has a consensus rating of “Buy” and an average target price of $7.75. ADC Therapeutics Trading Down 1.
2 % Shares of ADC Therapeutics stock opened at $1.21 on Tuesday. The business’s 50-day moving average price is $1.
54 and its 200-day moving average price is $2.09. The firm has a market capitalization of $119.
40 million, a PE ratio of -0.50 and a beta of 1.55.
ADC Therapeutics SA has a 12 month low of $1.05 and a 12 month high of $5.17.
ADC Therapeutics ( NYSE:ADCT – Get Free Report ) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.
35) by $0.06. The business had revenue of $19.
00 million for the quarter, compared to analysts’ expectations of $19.01 million. As a group, analysts predict that ADC Therapeutics SA will post -1.
69 earnings per share for the current fiscal year. ADC Therapeutics Profile ( Free Report ) ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.
S. Further Reading Five stocks we like better than ADC Therapeutics Insider Buying Explained: What Investors Need to Know Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Airline Stocks – Top Airline Stocks to Buy Now Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold How to Invest in Biotech Stocks 3 Hot New IPOs Defying the 2025 Market Slump Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
